Yuko Tsukamoto

763 total citations
17 papers, 606 citations indexed

About

Yuko Tsukamoto is a scholar working on Oncology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Yuko Tsukamoto has authored 17 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pharmacology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Yuko Tsukamoto's work include Pharmacogenetics and Drug Metabolism (5 papers), Cancer Treatment and Pharmacology (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Yuko Tsukamoto is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Cancer Treatment and Pharmacology (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Yuko Tsukamoto collaborates with scholars based in Japan, United States and Belgium. Yuko Tsukamoto's co-authors include William M. Sallas, Philip J. Lowe, Hiroyuki Kusuhara, Yoichiro Shibata, Honghui Zhou, Hugh M. Davis, Ikuo Horii, Brenda Temple, Stephanie A. Morris and Hideo Ishitsuka and has published in prestigious journals such as Pharmaceutical Research, British Journal of Clinical Pharmacology and Neuroscience Letters.

In The Last Decade

Yuko Tsukamoto

16 papers receiving 587 citations

Peers

Yuko Tsukamoto
Dietmar Schwab Switzerland
Jennifer Dong United States
David J. Sweeny United States
Eugene C. Chen United States
Haiqing Dai United States
Million Arefayene United States
Azher Hussain United States
Yoshiki Amuro Japan
Stella O. Sieber United States
Jun Eun Park South Korea
Dietmar Schwab Switzerland
Yuko Tsukamoto
Citations per year, relative to Yuko Tsukamoto Yuko Tsukamoto (= 1×) peers Dietmar Schwab

Countries citing papers authored by Yuko Tsukamoto

Since Specialization
Citations

This map shows the geographic impact of Yuko Tsukamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuko Tsukamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuko Tsukamoto more than expected).

Fields of papers citing papers by Yuko Tsukamoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuko Tsukamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuko Tsukamoto. The network helps show where Yuko Tsukamoto may publish in the future.

Co-authorship network of co-authors of Yuko Tsukamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Yuko Tsukamoto. A scholar is included among the top collaborators of Yuko Tsukamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuko Tsukamoto. Yuko Tsukamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Shimizu, Hiroko, Marc De Meulder, Srihari Gopal, et al.. (2019). Population Pharmacokinetics of Paliperidone Palmitate (Once‐Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia. Clinical Pharmacology in Drug Development. 9(2). 224–234. 6 indexed citations
2.
Tsukamoto, Yuko, Eiichiro Nagata, Naoto Fukuyama, et al.. (2016). Cilostazol protects against microvascular brain injury in a rat model of type 2 diabetes. Neuroscience Research. 117. 48–53. 6 indexed citations
3.
Shimizu, Tomoko, et al.. (2015). A case of primary cutaneous apocrine carcinoma of the left axilla. Skin Cancer. 30(3). 189–192.
4.
Fukuyama, Naoto, Yuko Tsukamoto, Shunya Takizawa, et al.. (2015). Altered blood flow in cerebral perforating arteries of rat models of diabetes: A synchrotron radiation microangiographic study toward clinical evaluation of white matter hyperintensities. Geriatrics and gerontology international. 15(S1). 74–80. 6 indexed citations
5.
Zhuang, Yanli, Zhenhua Xu, Dick E. de Vries, et al.. (2013). Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. International Journal of Clinical Pharmacology and Therapeutics. 51(3). 187–199. 20 indexed citations
6.
Zhou, Honghui, Yuko Tsukamoto, & Hugh M. Davis. (2011). Should Clinical Pharmacokinetic Bridging Studies Between Caucasian and Asian Populations Be Required for Approval of Monoclonal Antibodies?. The Journal of Clinical Pharmacology. 52(8). 1273–1276. 30 indexed citations
7.
Tsukamoto, Yuko, et al.. (2006). A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. British Journal of Clinical Pharmacology. 63(5). 548–561. 141 indexed citations
8.
Morris, Stephanie A., Yoichiro Shibata, Ken-ichi Noma, et al.. (2005). Histone H3 K36 Methylation Is Associated with Transcription Elongation in Schizosaccharomyces pombe. Eukaryotic Cell. 4(8). 1446–1454. 93 indexed citations
9.
Kato, Motohiro, Kōji Chiba, Akihiro Hisaka, et al.. (2003). The Intestinal First-pass Metabolism of Substrates of CYP3A4 and P-glycoprotei—Quantitative Analysis Based on Information from the Literature. Drug Metabolism and Pharmacokinetics. 18(6). 365–372. 74 indexed citations
10.
Blesch, Karen Smith, Ronald Gieschke, Yuko Tsukamoto, et al.. (2003). Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience. Investigational New Drugs. 21(2). 195–223. 41 indexed citations
11.
Ito, Kiyomi, Kōji Chiba, Masato Horikawa, et al.. (2002). Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?. PubMed. 4(4). 53–60. 69 indexed citations
12.
13.
Tsukamoto, Yuko, Yukio Kato, Masako Ura, et al.. (2001). A Physiologically Based Pharmacokinetic Analysis of Capecitabine, a Triple Prodrug of 5-FU, in Humans: The Mechanism for Tumor-Selective Accumulation of 5-FU. Pharmaceutical Research. 18(8). 1190–1202. 65 indexed citations
14.
15.
16.
Tsukamoto, Yuko, et al.. (1995). Lack of an Effect of Madopar on the Disposition of Tolcapone and its 3-O-Methylated Metabolite in Rats. Journal of Pharmacy and Pharmacology. 47(6). 539–542. 6 indexed citations
17.
Tsukamoto, Yuko, et al.. (1994). The Disposition of the Tolcapone 3-O-Methylated Metabolite is Affected by the Route of Administration in Rats. Journal of Pharmacy and Pharmacology. 46(7). 571–574. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dietmar Schwab Breakdown of academic impact, for papers by Jennifer Dong Breakdown of academic impact, for papers by David J. Sweeny Breakdown of academic impact, for papers by Eugene C. Chen Breakdown of academic impact, for papers by Haiqing Dai Breakdown of academic impact, for papers by Million Arefayene Breakdown of academic impact, for papers by Azher Hussain Breakdown of academic impact, for papers by Yoshiki Amuro Breakdown of academic impact, for papers by Stella O. Sieber Breakdown of academic impact, for papers by Jun Eun Park
Rankless by CCL
2026